PRMT5 Inhibition Enhances Elimination of FLT3-ITD AML Stem Cells in Combination with TKI Treatment

被引：1
|
作者：
Kumar, Harish [1 ]
Dhir, Aditi [2 ]
Paterson, Andrew J. [3 ]
Anderson, Nick R. [4 ]
Qiu, Shaowei [4 ]
Zhao, Xinyang [5 ]
Lu, Rui [4 ]
Bhatia, Ravi [4 ]
机构：
[1] Univ Alabama Birmingham, Dept Med, UAB, Div Hematol & Oncol, Birmingham, AL 35294 USA
[2] Univ Alabama Birmingham, Birmingham, AL 35294 USA
[3] Univ Alabama Birmingham, Div Endocrinol Diabet & Metab, Birmingham, AL 35294 USA
[4] Univ Alabama Birmingham, Div Hematol & Oncol, Dept Med, Birmingham, AL 35294 USA
[5] Univ Alabama Birmingham, Dept Biochem & Mol Genet, Birmingham, AL 35294 USA
来源：
BLOOD | 2022年 / 140卷
关键词：
D O I：
10.1182/blood-2022-168326
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：3073 / 3074
页数：2
相关论文
共 50 条
  • [41] Inhibition of heme oxygenase 1 decreases proliferation and resensitizes TKI-resistant Flt3-ITD-positive AML cells
    Irwin, Mary E.
    Chandra, Joya
    CANCER RESEARCH, 2015, 75
  • [42] Influence of FLT3-ITD Mutation and Length on the Treatment Response and Prognosis in Cytogenetically Normal AML Patients
    Jiang, Xuejie
    Yin, Changxin
    Sun, Junya
    Cheng, Jiaying
    Wang, Qiang
    Yu, Guopan
    Jiang, Ling
    Xu, Dan
    Liu, Xiaoli
    Feng, Ru
    Liu, Qifa
    BLOOD, 2018, 132
  • [43] Treatment of Post-transplant Relapse of FLT3-ITD Mutated AML Using 5-Azacytidine and Sorafenib Bitherapy
    Sid, Selim
    Rey, Jerome
    Charbonnier, Aude
    D'Incan, Evelyne
    Mohty, Bilal
    Blaise, Didier
    Vey, Norbert
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 (04): : 241 - 242
  • [44] Prolonged Remission of FLT3-ITD Positive AML Treated With Sorafenib Post Allogeneic Stem Cell Transplantation
    Moukadem, Hiba
    Antar, Ahmad
    Kharfan-Dabaja, Mohamed
    Bazarbachi, Ali
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2014, 14 : S126 - S127
  • [45] Dual Inhibition of Aurora and FLT3 Kinases by CCT137690: A Novel Treatment Strategy Against FLT3-ITD Positive AML In Vitro and In Vivo
    Moore, Andrew S.
    Faisal, Amir
    Bavetsias, Vassilios
    Sun, Chongbo
    Atrash, Butrus
    Valenti, Melanie
    Brandon, Alexis de Haven
    Avery, Sian
    Raynaud, Florence I.
    Workman, Paul
    Pearson, Andrew D. J.
    Blagg, Julian
    Eccles, Suzanne A.
    Linardopoulos, Spiros
    BLOOD, 2010, 116 (21) : 1347 - 1348
  • [46] Mechanisms of apoptosis induction by simultaneous inhibition of PI3K and FLT3-ITD in AML cells in the hypoxic bone marrow microenvironment
    Jin, Linhua
    Tabe, Yoko
    Lu, Hongbo
    Borthakur, Gautam
    Miida, Takashi
    Kantarjian, Hagop
    Andreeff, Michael
    Konopleva, Marina
    CANCER LETTERS, 2013, 329 (01) : 45 - 58
  • [47] FLT3 INHIBITION OVERCOMES RESISTANCE TO THE BCL-2 SELECTIVE ANTAGONIST, VENETOCLAX, IN FLT3-ITD MUTANT AML MODELS
    Sampath, D.
    Mali, R.
    Lasater, E.
    Doyle, K.
    Malla, R.
    Boghaert, E.
    Souers, A.
    Leverson, J.
    HAEMATOLOGICA, 2017, 102 : 42 - 42
  • [48] FLT3-ITD INDUCED MYELOPROLIFERATION CAUSES A CELL EXTRINSIC DEPLETION OF HAEMATOPOIETIC STEM CELLS
    Mead, A. J.
    Atkinson, D.
    Kharazi, S.
    Chowdhury, O.
    Clark, S. A.
    Matsuoka, S.
    Bouriez-Jones, T.
    Facchini, R.
    Booth, C.
    Woll, P.
    Suda, T.
    Nerlov, C.
    Jacobsen, S. E.
    HAEMATOLOGICA, 2014, 99 : 256 - 256
  • [49] Characteristics of FLT3-ITD and Efficacy of Sorafenib Treatment in Pediatric AML: A Report from AML-BFM Study Group
    Antoniou, Evangelia
    Puschnig, Annika
    Hoffmeister, Lina Marie
    Awada, Amani
    Von Neuhoff, Nils
    Schneider, Markus
    Reinhardt, Dirk
    Niktoreh, Naghmeh
    BLOOD, 2023, 142
  • [50] AXL is responsible for much of TKI-mediated adaptive resistance in FLT3/ITD AML cells
    Seale, Tessa
    Li, Li
    Seo, Jaesung
    Nguyen, Bao
    Levis, Mark
    Pratilas, Christine
    Small, Donald
    CANCER RESEARCH, 2022, 82 (12)
12345